Qfitlia
Apr 07, 2025
Sanofi’s Qfitlia Enters the Hemophilia Market—What Sets It Apart?
Over the past three years, the FDA has approved six new hemophilia treatments, including three gene therapies. Now, Sanofi’s Qfitlia (fitusiran) enters the competitive hemophilia therapeutics market, distinguishing itself as the only therapy approved for all types of hemophilia. Unlike most existing treatments, Qfi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
